



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

October 6, 2022

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code - 532523</b>	<b>Scrip Symbol - Biocon</b>

**Subject: Notification to Stock Exchanges**

Dear Sir/Madam,

*“This is to inform you that the European Directorate for the Quality of Medicines & HealthCare (EDQM) conducted a GMP inspection of an API manufacturing site of Biocon Limited in Bangalore from the 12<sup>th</sup> to 14<sup>th</sup> of September 2022 and issued a list of deficiencies on 5<sup>th</sup> October 2022. There were no critical deficiencies and one deficiency cited under the category ‘Major’. We will be responding to the agency with appropriate corrective and preventive actions within the stipulated time. Biocon remains committed to the Quality, Safety & Efficacy of its products.”*

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

---

**Mayank Verma**  
Company Secretary and Compliance Officer